DOI: 10.1111/ajd.14139 ISSN: 0004-8380

A real‐world Australian experience of upadacitinib for the treatment of severe atopic dermatitis

Vanessa Tran, Gayle Ross
  • Dermatology

Abstract

Upadacitinib is a selective Janus kinase‐1 (JAK‐1) inhibitor that has been shown in clinical trials to be effective for the treatment of moderate‐to‐severe atopic dermatitis (AD). This study aimed to evaluate the real‐world experience of patients with AD treated with upadacitinib in a single‐centre Australian cohort. Our study revealed a higher propensity for herpetic infections compared with previous randomised controlled trials (RCTs).

More from our Archive